8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Mar 17, 2026·SEC
Material company update
Mar 12, 2026·SEC
Precision BioSciences, Inc.(DTIL)Earnings, Financials & Key Ratios
DTIL•NASDAQ
Price updated Jun 19, 2026
AboutPrecision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Show more
- Revenue$34M-50.1%
- EBITDA-$49M-128.8%
- Net Income-$47M-750.3%
- EPS (Diluted)-3.63-449.0%
- Gross Margin91.97%-8.0%
- EBITDA Margin-144.16%-358.8%
- Operating Margin-152.19%-299.6%
- Net Margin-136.03%-1403.8%
- ROE-62.71%-429.2%
DTIL Key Insights
Precision BioSciences, Inc. (DTIL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 15.6%
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Shares diluted 86.3% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when DTIL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DTIL Price & Volume
Precision BioSciences, Inc. (DTIL) stock price & volume — 10-year historical chart
Loading chart...
DTIL Growth Metrics
Precision BioSciences, Inc. (DTIL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years7.13%
3 Years10.93%
TTM-11.87%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-102.33%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-56.96%
Return on Capital
10 Years-36.65%
5 Years-31.02%
3 Years-30.68%
Last Year-39.08%
DTIL Recent Earnings
Precision BioSciences, Inc. (DTIL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.75-14.5%
$0.66
Rev
$11M+167.6%
$4M
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.36+271.4%
$0.21
Rev
$34M+276.9%
$9M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$1.84-493.5%
$0.31
Rev
$13,000-99.9%
$9M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$2.13-2266.7%
$0.09
Rev
$18,000-99.7%
$5M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.75vs $0.66-14.5% | $11Mvs $4M+167.6% |
| Q2 2026 | Mar 12, 2026 | $0.36vs $0.21+271.4% | $34Mvs $9M+276.9% |
| Q4 2025 | Nov 3, 2025 | $1.84vs $0.31-493.5% | $13,000vs $9M-99.9% |
| Q3 2025 | Aug 7, 2025 | $2.13vs $0.09-2266.7% | $18,000vs $5M-99.7% |
Based on last 12 quarters of dataView full earnings history →
DTIL Peer Comparison
Precision BioSciences, Inc. (DTIL) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 SANA | 876.62M | 3.15 | -3.28 | -161.87% | 0.49 | |||
 ALLO | 487.74M | 2.00 | -2.30 | -100% | -56.45% | 0.26 | ||
 PGEN | 1.45B | 4.82 | -3.42 | 146.73% | -6.47% | -17.69% | 0.24 |
Compare DTIL vs Peers
Precision BioSciences, Inc. (DTIL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DTIL Income Statement
Precision BioSciences, Inc. (DTIL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 6.48M | 10.88M | 22.24M | 24.29M | 115.53M | 25.1M | 48.73M | 68.7M | 34.26M | 45.07M |
Revenue Growth % | -7.57% | 67.84% | 104.34% | 9.21% | 375.72% | -78.28% | 94.15% | 40.98% | -50.12% | -11.87% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.75M | 1.37M |
COGS % of Revenue | - | - | - | - | - | - | - | - | 8.03% | - |
Gross Profit | 6.48M▲ 0% | 10.88M▲ 67.8% | 22.24M▲ 104.3% | 24.29M▲ 9.2% | 115.53M▲ 375.7% | 25.1M▼ 78.3% | 48.73M▲ 94.1% | 68.7M▲ 41.0% | 31.51M▼ 54.1% | 43.7M▲ 0% |
Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 91.97% | 96.95% |
Gross Profit Growth % | -7.57% | 67.84% | 104.34% | 9.21% | 375.72% | -78.28% | 94.15% | 40.98% | -54.13% | - |
Operating Expenses | 28.34M | 58.8M | 109.44M | 134.11M | 154.91M | 87.41M | 92.46M | 94.86M | 83.66M | 82.81M |
OpEx % of Revenue | 437.08% | 540.25% | 492.14% | 552.25% | 134.08% | 348.26% | 189.76% | 138.08% | 244.16% | - |
Selling, General & Admin | 8.02M | 13.67M | 27.03M | 36.05M | 39.67M | 41.28M | 39.09M | 35.3M | 32.24M | 30.49M |
SG&A % of Revenue | 123.63% | 125.64% | 121.53% | 148.45% | 34.34% | 164.49% | 80.22% | 51.38% | 94.09% | - |
Research & Development | 20.32M | 45.12M | 82.42M | 98.06M | 115.24M | 46.12M | 53.38M | 59.56M | 54.17M | 53.36M |
R&D % of Revenue | 313.45% | 414.61% | 370.61% | 403.79% | 99.75% | 183.77% | 109.54% | 86.7% | 158.1% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.75M | -1.04M |
Operating Income | -21.97M▲ 0% | -47.91M▼ 118.0% | -87.2M▼ 82.0% | -109.83M▼ 25.9% | -39.38M▲ 64.1% | -62.31M▼ 58.2% | -43.74M▲ 29.8% | -26.16M▲ 40.2% | -52.15M▼ 99.3% | -39.11M▲ 0% |
Operating Margin % | -338.9% | -440.25% | -392.14% | -452.25% | -34.08% | -248.26% | -89.76% | -38.08% | -152.19% | -86.77% |
Operating Income Growth % | -148.91% | -118.04% | -82.01% | -25.94% | 64.15% | -58.24% | 29.81% | 40.18% | -99.33% | - |
EBITDA | -20.54M | -45.56M | -81.89M | -100.02M | -29.18M | -53.3M | -35.48M | -21.59M | -49.4M | -36.42M |
EBITDA Margin % | -316.76% | -418.62% | -368.23% | -411.84% | -25.26% | -212.38% | -72.82% | -31.42% | -144.16% | -80.81% |
EBITDA Growth % | -150.84% | -121.81% | -79.74% | -22.14% | 70.83% | -82.68% | 33.44% | 39.16% | -128.84% | 9.47% |
D&A (Non-Cash Add-back) | 1.44M | 2.35M | 5.32M | 9.81M | 10.2M | 9M | 8.26M | 4.58M | 2.75M | 2.69M |
EBIT | -21.86M | -46.04M | -92.69M | -109.01M | -30.47M | -71.8M | -40.3M | 8.95M | -52.15M | -34.05M |
Net Interest Income | 872K | 1.88M | 4.08M | 822K | 76K | 2.36M | 5.46M | 4.98M | 2.82M | 2.54M |
Interest Income | 872K | 1.88M | 4.27M | 822K | 208K | 3.47M | 7.69M | 6.76M | 4.24M | 3.92M |
Interest Expense | 0 | 0 | 182K | 0 | 132K | 1.11M | 2.23M | 1.78M | 1.42M | 1.38M |
Other Income/Expense | 872K | 1.88M | -5.67M | 822K | 8.77M | -10.6M | 1.21M | 33.33M | 5.54M | -5.37M |
Pretax Income | -21.1M▲ 0% | -46.04M▼ 118.2% | -92.88M▼ 101.7% | -109.01M▼ 17.4% | -30.6M▲ 71.9% | -72.91M▼ 138.2% | -42.53M▲ 41.7% | 7.17M▲ 116.9% | -46.61M▼ 750.3% | -44.48M▲ 0% |
Pretax Margin % | -325.45% | -423.02% | -417.65% | -448.86% | -26.49% | -290.5% | -87.28% | 10.43% | -136.03% | -98.7% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -21.1M▲ 0% | -46.04M▼ 118.2% | -92.88M▼ 101.7% | -109.01M▼ 17.4% | -30.6M▲ 71.9% | -111.64M▼ 264.8% | -61.32M▲ 45.1% | 7.17M▲ 111.7% | -46.61M▼ 750.3% | -44.48M▲ 0% |
Net Margin % | -325.45% | -423.02% | -417.65% | -448.86% | -26.49% | -444.8% | -125.84% | 10.43% | -136.03% | -98.7% |
Net Income Growth % | -155.75% | -118.16% | -101.74% | -17.37% | 71.93% | -264.8% | 45.07% | 111.69% | -750.33% | -102.33% |
Net Income (Continuing) | -21.1M | -46.04M | -92.88M | -109.01M | -30.6M | -72.91M | -42.53M | 7.17M | -46.61M | -44.48M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | -38.73M | -18.79M | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -18.81▲ 0% | -28.17▼ 49.8% | -59.50▼ 111.2% | -62.85▼ 5.6% | -15.60▲ 75.2% | -38.10▼ 144.2% | -15.96▲ 58.1% | 1.04▲ 106.5% | -3.63▼ 449.0% | -1.81▲ 0% |
EPS Growth % | -3738.78% | -49.76% | -111.22% | -5.63% | 75.18% | -144.23% | 58.11% | 106.52% | -449.04% | -56.96% |
EPS (Basic) | -18.81 | -28.17 | -59.50 | -62.85 | -15.60 | -38.10 | -15.96 | 1.05 | -3.63 | - |
Diluted Shares Outstanding | 1.12M | 1.63M | 1.4M | 1.73M | 1.96M | 2.93M | 3.84M | 6.88M | 12.83M | 24.63M |
Basic Shares Outstanding | 1.12M | 1.63M | 1.4M | 1.73M | 1.96M | 2.93M | 3.84M | 6.83M | 12.83M | 24.63M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
DTIL Balance Sheet
Precision BioSciences, Inc. (DTIL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 64.33M | 115.67M | 193.67M | 105.56M | 161.75M | 199.1M | 136.36M | 94.99M | 118.74M | 108.69M |
Cash & Short-Term Investments | 62.8M | 103.19M | 180.89M | 89.8M | 143.66M | 189.58M | 116.68M | 86.31M | 115.58M | 101.18M |
Cash Only | 62.8M | 103.19M | 180.89M | 89.8M | 143.66M | 189.58M | 116.68M | 85.9M | 110.82M | 99.37M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 413K | 4.76M | 1.81M |
Accounts Receivable | 22K | 523K | 965K | 10M | 488K | 720K | 12.8M | 1.7M | 0 | 4M |
Days Sales Outstanding | 1.24 | 17.54 | 15.84 | 150.3 | 1.54 | 10.47 | 95.87 | 9.02 | - | 8.11 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 70K | 3.05M | 2.32M | 4K | 169K | 2.78M | 906K | 538K | 3.15M | 3.51M |
Total Non-Current Assets | 8.35M | 22.93M | 41.56M | 44.59M | 49.74M | 39.06M | 23.42M | 41.4M | 35.68M | 35.2M |
Property, Plant & Equipment | 8.14M | 21.15M | 39.57M | 41.5M | 29.33M | 13.78M | 14.6M | 10.18M | 7.23M | 6.65M |
Fixed Asset Turnover | 0.80x | 0.51x | 0.56x | 0.59x | 3.94x | 1.82x | 3.34x | 6.75x | 4.74x | 7.63x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 90K | 1.47M | 1.43M | 1.37M | 2.05M | 731K | 400K | 622K | 1.17M | 1.13M |
Long-Term Investments | 0 | 0 | 0 | 0 | 6.84M | 4.75M | 3.21M | 3.21M | 744K | 34.69M |
Other Non-Current Assets | 124K | 312K | 558K | 1.72M | 11.52M | 19.81M | 5.21M | 27.39M | 26.54M | 26.68M |
Total Assets | 72.68M▲ 0% | 138.6M▲ 90.7% | 235.23M▲ 69.7% | 150.16M▼ 36.2% | 211.5M▲ 40.9% | 238.17M▲ 12.6% | 159.78M▼ 32.9% | 136.39M▼ 14.6% | 154.42M▲ 13.2% | 143.89M▲ 0% |
Asset Turnover | 0.09x | 0.08x | 0.09x | 0.16x | 0.55x | 0.11x | 0.30x | 0.50x | 0.22x | 0.36x |
Asset Growth % | -26.15% | 90.69% | 69.72% | -36.17% | 40.85% | 12.61% | -32.91% | -14.64% | 13.22% | -44.41% |
Total Current Liabilities | 9.2M | 14.07M | 26.93M | 42.83M | 35.98M | 59.66M | 49.99M | 14.98M | 8.91M | 7.75M |
Accounts Payable | 1.81M | 2.22M | 2.04M | 792K | 1.14M | 653K | 2.97M | 1.31M | 296K | 944K |
Days Payables Outstanding | - | - | - | - | - | - | - | - | 39.24 | 245.79 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 22.41M | 0 | 1.51M | 1.56M |
Deferred Revenue (Current) | 5.82M | 8.44M | 16.49M | 30.24M | 21.24M | 46.19M | 12.04M | 2.96M | 0 | 12.24M |
Other Current Liabilities | 590K | 2.46M | 6.01M | 6.6M | 7.74M | 9.31M | 9.88M | 7.38M | 7.11M | 5.25M |
Current Ratio | 6.99x | 8.22x | 7.19x | 2.46x | 4.50x | 3.34x | 2.73x | 6.34x | 13.32x | 14.02x |
Quick Ratio | 6.99x | 8.22x | 7.19x | 2.46x | 4.50x | 3.34x | 2.73x | 6.34x | 13.32x | 14.02x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -237.68 |
Total Non-Current Liabilities | 89.85M | 84.56M | 69.99M | 62.9M | 84.35M | 118.07M | 90.93M | 65.02M | 53.26M | 60.03M |
Long-Term Debt | 0 | 0 | 0 | 0 | 2.48M | 22.22M | 0 | 22.32M | 22.4M | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 8.59M | 4.81M | 1.06M | 7.72M | 6.4M | 4.9M | 15.87M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1.25M | 1.76M | 4.09M | 392K | 44K | 1.92M | 128K | 2.99M | 15.95M | 60.03M |
Total Liabilities | 99.05M | 98.64M | 96.92M | 105.73M | 120.33M | 177.74M | 140.92M | 80M | 62.17M | 67.79M |
Total Debt | 0 | 0 | 0 | 10.52M | 9.11M | 24.96M | 31.27M | 30.05M | 28.81M | 1.56M |
Net Debt | -62.8M | -103.19M | -180.89M | -79.28M | -134.55M | -164.62M | -85.41M | -55.85M | -82.02M | -97.81M |
Debt / Equity | - | - | - | 0.24x | 0.10x | 0.41x | 1.66x | 0.53x | 0.31x | 0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.04x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 2.69x |
Interest Coverage | - | - | -509.31x | - | -230.83x | -64.62x | -18.07x | 5.02x | -36.67x | -24.69x |
Total Equity | -26.37M▲ 0% | 39.96M▲ 251.5% | 138.31M▲ 246.1% | 44.42M▼ 67.9% | 91.17M▲ 105.2% | 60.43M▼ 33.7% | 18.86M▼ 68.8% | 56.39M▲ 199.0% | 92.25M▲ 63.6% | 76.1M▲ 0% |
Equity Growth % | -455.25% | 251.54% | 246.13% | -67.88% | 105.22% | -33.71% | -68.79% | 198.99% | 63.58% | -10.95% |
Book Value per Share | -23.51 | 24.45 | 98.80 | 25.61 | 46.60 | 20.63 | 4.91 | 8.19 | 7.19 | 3.09 |
Total Shareholders' Equity | -26.37M | 39.96M | 138.31M | 44.42M | 91.17M | 60.43M | 18.86M | 56.39M | 92.25M | 76.1M |
Common Stock | 0 | 0 | 0 | 0 | 0 | 1K | 1K | 1K | 1K | 1K |
Retained Earnings | -39.11M | -85.19M | -177.07M | -286.07M | -316.68M | -428.31M | -489.63M | -482.46M | -528.19M | -546.63M |
Treasury Stock | -952K | -952K | -952K | -952K | -952K | -952K | -952K | -952K | -952K | 0 |
Accumulated OCI | -3.19M | -5.48M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DTIL Cash Flow Statement
Precision BioSciences, Inc. (DTIL) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -24.17M | -51.72M | -73.64M | -87.39M | -10.85M | -45.75M | -84.11M | -58.45M | -65.84M | -58.73M |
Operating CF Margin % | -372.75% | -475.26% | -331.13% | -359.84% | -9.39% | -182.3% | -172.62% | -85.08% | -192.16% | - |
Operating CF Growth % | -126.19% | -114.01% | -42.37% | -18.67% | 87.58% | -321.57% | -83.84% | 30.52% | -12.66% | -117.49% |
Net Income | -21.1M | -46.04M | -92.88M | -109.01M | -30.6M | -111.64M | -61.32M | 7.17M | -45.72M | -44.48M |
Depreciation & Amortization | 1.44M | 2.35M | 5.32M | 9.81M | 10.2M | 9M | 8.26M | 4.58M | 2.75M | 2.69M |
Stock-Based Compensation | 419K | 2.45M | 0 | 13.79M | 16.51M | 19.2M | 14.04M | 12.6M | 10.19M | 8.91M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 174K | 14K | 16.28M | 35K | -26.55M | 13.57M | -3.6M | -28.79M | -8.35M | -3.78M |
Working Capital Changes | -5.09M | -10.51M | -2.36M | -2.01M | 19.58M | 24.11M | -41.49M | -54M | -24.71M | -22.95M |
Change in Receivables | 0 | -523K | -441K | -9.04M | 9.51M | -232K | -181K | 10.42M | 229K | -5.46M |
Change in Inventory | 0 | -5.95M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 864K | -673K | 667K | -1.46M | 867K | 153K | 1.51M | -2.1M | -737K | 17K |
Cash from Investing | -5.51M | -15.66M | -24.67M | -5.03M | -5.8M | -3.32M | 5.83M | -215K | -634K | -434K |
Capital Expenditures | -5.57M | -15.68M | -24.67M | -5.03M | -5.05M | -3.32M | -2.28M | -250K | -85K | -69K |
CapEx % of Revenue | 85.83% | 144.06% | 110.92% | 20.72% | 4.37% | 13.22% | 4.67% | 0.36% | 0.25% | 0.15% |
Acquisitions | 50K | 15K | 0 | 0 | 0 | 0 | 8M | 60K | 0 | 27K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 50K | 15K | 0 | 0 | -750K | 0 | 107K | -25K | -549K | -392K |
Cash from Financing | -937K | 107.78M | 176M | 1.33M | 70.52M | 94.98M | 5.39M | 50.45M | 95.16M | 85.22M |
Debt Issued (Net) | 0 | 0 | 39.55M | 0 | 2.47M | 19.8M | 0 | -37K | 0 | 0 |
Equity Issued (Net) | -952K | 109.74M | 136.45M | 0 | 60.48M | 74.34M | 4.99M | 50.24M | 95.16M | 84.47M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -952K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 15K | -1.97M | 0 | 1.33M | 7.57M | 835K | 401K | 249K | 0 | 745K |
Net Change in Cash | -30.62M▲ 0% | 40.39M▲ 231.9% | 77.69M▲ 92.4% | -91.09M▼ 217.2% | 53.87M▲ 159.1% | 45.91M▼ 14.8% | -72.9M▼ 258.8% | -8.21M▲ 88.7% | 28.68M▲ 449.4% | 22.28M▲ 0% |
Free Cash Flow | -29.73M▲ 0% | -67.4M▼ 126.7% | -98.3M▼ 45.8% | -92.42M▲ 6.0% | -16.66M▲ 82.0% | -49.07M▼ 194.6% | -86.39M▼ 76.1% | -58.7M▲ 32.1% | -65.93M▼ 12.3% | -58.78M▲ 0% |
FCF Margin % | -458.57% | -619.32% | -442.05% | -380.55% | -14.42% | -195.52% | -177.3% | -85.44% | -192.41% | -130.42% |
FCF Growth % | -132.96% | -126.68% | -45.85% | 5.99% | 81.98% | -194.62% | -76.05% | 32.06% | -12.32% | 0.4% |
FCF per Share | -26.51 | -41.24 | -70.22 | -53.28 | -8.51 | -16.75 | -22.49 | -8.53 | -5.14 | -2.39 |
FCF Conversion (FCF/Net Income) | 1.15x | 1.12x | 0.79x | 0.80x | 0.35x | 0.41x | 1.37x | -8.15x | 1.41x | 1.32x |
Interest Paid | 0 | 0 | 0 | 0 | 68K | 824K | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DTIL Key Ratios
Precision BioSciences, Inc. (DTIL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -677.46% | -104.2% | -119.3% | -45.14% | -147.28% | -154.66% | 19.05% | -62.71% | -81.24% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | -726.16% | 1257.59% |
Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 91.97% | 96.95% |
Net Margin | -325.45% | -423.02% | -417.65% | -448.86% | -26.49% | -444.8% | -125.84% | 10.43% | -136.03% | -98.7% |
Debt / Equity | - | - | - | 0.24x | 0.10x | 0.41x | 1.66x | 0.53x | 0.31x | 0.02x |
Interest Coverage | - | - | -509.31x | - | -230.83x | -64.62x | -18.07x | 5.02x | -36.67x | -24.69x |
FCF Conversion | 1.15x | 1.12x | 0.79x | 0.80x | 0.35x | 0.41x | 1.37x | -8.15x | 1.41x | 1.32x |
Revenue Growth | -7.57% | 67.84% | 104.34% | 9.21% | 375.72% | -78.28% | 94.15% | 40.98% | -50.12% | -11.87% |
Related:DTIL Dividend History·DTIL Revenue History·DTIL Price History·DTIL P/E History·DTIL Financial Ratios·DTIL Institutional Holders
DTIL SEC Filings & Documents
Precision BioSciences, Inc. (DTIL) SEC filings — annual & quarterly reports (10-K, 10-Q)
DTIL Frequently Asked Questions
Precision BioSciences, Inc. (DTIL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Precision BioSciences, Inc. (DTIL) reported $45.1M in revenue for fiscal year 2025. This represents a 543% increase from $7.0M in 2016.
Precision BioSciences, Inc. (DTIL) saw revenue decline by 50.1% over the past year.
Precision BioSciences, Inc. (DTIL) reported a net loss of $44.5M for fiscal year 2025.
Dividend & Returns
Precision BioSciences, Inc. (DTIL) has a return on equity (ROE) of -62.7%. Negative ROE indicates the company is unprofitable.
Precision BioSciences, Inc. (DTIL) had negative free cash flow of $58.8M in fiscal year 2025, likely due to heavy capital investments.